(British Approved Name, rINN)
Pharmacopoeias. In US.
The United States Pharmacopeia 31, 2008 (Ondansetron). A white to off-white powder. Sparingly soluble in water very soluble in acid solutions. Store in airtight containers. Protect from light.
(BANM, US Adopted Name, rINNM)
Pharmacopoeias. In China, International, and US.
European Pharmacopoeia, 6th ed. (Ondansetron Hydrochloride Dihydrate). A white or almost white powder. Sparingly soluble in water and in alcohol slightly soluble in dichloromethane soluble in methyl alcohol. Protect from light.
The United States Pharmacopeia 31, 2008 (Ondansetron Hydrochloride). A white to off-white powder. Sparingly soluble in water and in alcohol very slightly soluble in acetone, in chloroform, and in ethyl acetate slightly soluble in dichloromethane and in isopropyl alcohol soluble in methyl alcohol. Store in airtight containers at a temperature of 25°, excursions permitted between 15° and 30°. Protect from light.
Incompatibility. Ondansetron hydrochloride and dexamethasone sodium phosphate were not compatible when high concentrations were combined in polypropylene syringes. Lower concentrations (up to 640 micrograms/mL of ondansetron and 400 micrograms/mL of dexamethasone phosphate) were stable in 50 mL containers of infusion fluid for 30 days under refrigeration. Compatibility has been reported for 24 hours in plastic syringes at 4° or 23° with a variety of other drugs, and with several antineoplastics (cytarabine, dacarbazine, doxorubicin, etoposide, or methotrexate) in P VC infusion bags for 48 hours at room temperature.
Adverse Effects and Precautions
Ondansetron and other 5-HT3 antagonists may cause headache, a sensation of flushing or warmth, hiccups, and constipation. A transient rise in liver enzymes has occasionally occurred. There have been rare reports of immediate hypersensitivity reactions, including anaphylaxis. Chest pain, arrhythmias, hypotension, tachycardia, and bradycardia have been reported rarely. Dizziness and transient visual disturbances such as blurred vision (or very rarely, transient blindness) have been reported during rapid intravenous injection. Transient ECG changes including QT interval prolongation have occurred very rarely, mainly with intravenous ondansetron. Seizures and movement disorders, including extrapyramidal reactions such as dystonia, dyskinesia, and oculogyric crisis have been reported. Rashes and urticaria have also occurred. Injection site reactions may develop, and local burning sensations are common after insertion of suppositories. 5-HT3 antagonists should generally not be used in patients who have had a hypersensitivity reaction to a member of this drug class. They should be used with care in patients with signs of subacute intestinal obstruction or ileus. Ondansetron should be given in reduced doses to patients with moderate to severe hepatic impairment.
Effects on the cardiovascular system. Chest pain and/or cardiac arrhythmias that might have been associated with ondansetron were reported in 4 patients, 2 of whom died. In 3 subsequent patients who developed severe chest or anginal pain, treatment with ondansetron was stopped. The manufacturers (Glaxo) had at that time no evidence of a causal relationship between ondansetron and episodes of chest pain and cardiac abnormalities. Giving ondansetron or granisetron intravenously produced no clinically important cardiovascular changes in a study in 12 healthy subjects. Since then, however, myocardial ischaemia has been reported with both ondansetron and dolasetron in the latter case this led to an acute myocardial infarction. Supraventricular tachycardia reported with dolasetron was attributed to an interaction with sevoflurane. Another study in healthy subjects found that dolasetron mainly altered ECG parameters indicative of ventricular depolarisation, whereas ondansetron affected mainly ventricular repolarisation. However, ECG changes were transient and asymptomatic. Studies of high-dose intravenous granisetron found no significant adverse effects on pulse, blood pressure, or ECG measurements. A review of the electrocardiographic and cardiovascular effects of the 5-HT3 antagonists concluded that although this class of drugs may cause small, transient ECG changes, the clinical benefits of the drugs outweighed the small theoretical risk of any clinically significant cardiovascular events. Nonetheless, the use of dolasetron in children has been contra-indicated in the UK (see Uses and Administration).
Effects on the eyes. Blurring followed by transient loss of vision has been reported after rapid intravenous injection of ondansetron. Oculogyric crisis may occur as part of extrapyramidal reactions seen with ondansetron, see Effects on the Nervous System, below.
Effects on the liver. Although disturbances in liver enzyme values have been reported in patients given ondansetron, more severe symptoms of liver disorder appear to be very rare however, there is a report of severe jaundice associated with ondansetron as an antiemetic for chemotherapy. Symptoms did not recur when the patient received granisetron.
Effects on the nervous system. Tonic-clonic movements and frothing at the mouth occurred in a patient 90 minutes after an infusion of ondansetron the patient responded to diazepam intravenously. The manufacturers had seen 10 patients who developed seizures during initial clinical studies, but considered that, unlike this case, all these patients had predisposing factors. Hypotension and generalised tonic-clonic seizures were reported in a patient with metastatic breast cancer given ondansetron as an intravenous bolus. Although seizures might have been due to brain metastases, the authors concluded that ondansetron had been the likely cause, since the patient experienced no further problems when antiemetic therapy was changed to metoclopramide. Extrapyramidal reactions in patients given ondansetron as part of a chemotherapy regimen’ and for postoperative nausea and vomiting have also been reported. In one case, transient multifocal encephalopathy developed. Clinical manifestations such as clonus, oculogyric crisis, and oromandibular and limb dystonia resembled those of structural brain injury, and response to diphenhydramine was poor despite this, the patient made a full neurological recovery over the course of 12 hours.
Hypersensitivity. Anaphylactoid reactions have been reported in patients given ondansetron injections. The FDA stated in October 1993 that it had received 24 reports of such reactions, mostly occurring after the first ondansetron dose of the second or third chemotherapy cycle, and characterised by urticaria, an-gioedema, hypotension, bronchospasm, and dyspnoea. Similar effects have been reported in a patient with no prior exposure to ondansetron.
Cross-sensitivity between 5-HT3 antagonists has been reported 2 patients who had had a mild hypersensitivity reaction to one 5-HT3 antagonist developed a more severe reaction after exposure to another. In the first case severe acute asthma, cyanosis, and loss of consciousness developed after ondansetron in a patient who had previously experienced an asthmatic reaction after tropisetron. The second patient had developed pruritus after a tropisetron inj ection and urticaria after ondansetron, and subsequently developed anaphylactic shock 5 minutes after a further dose of tropisetron. It was recommended that another 5-HT3 antagonist should not be given as a replacement to patients who developed a hypersensitivity reaction to a drug of this class.
Ondansetron does not appear to induce or inhibit the cytochrome P450 isoenzyme system, but it is itself metabolised by multiple hepatic isoenzymes, including CYP3A4, CYP2D6, and CYP1A2. US licensed product information states that inducers or inhibitors of these isoenzymes may change the clearance and half-life of ondansetron, but that on the basis of available data, no dose adjustments are recommended. UK licensed product information states that enzyme inhibition of one isoenzyme is usually compensated for by other enzymes and should result in little or no significant change in overall ondansetron clearance or dose requirement. Potent inducers of CYP3A4, such as phenytoin, carbamazepine, and rifampicin, have been reported to increase ondansetron clearance and reduce ondansetron plasma concentrations. Because of the reports of transient ECG changes in some patients taking 5-HT3 antagonists (see above), there is a theoretical need for caution if given with other drugs that prolong QT-interval however, clinical evidence of a significant interaction seems to be mostly lacking.
Analgesics. For evidence of reduced analgesic efficacy of tramadol in patients also given 5-HT3-receptor antagonists, such as ondansetron.
Antibacterials. Rifampicin pretreatment reduced the area under the plasma concentration-time curve of oral ondansetron by 65% and of intravenous ondansetron by 48% in healthy subjects. Use of rifampicin, or other potent inducers of cytochrome P450 isoenzyme CYP3A4, with ondansetron may reduce antiemetic efficacy.
Antineoplastics. For mention of retrospective studies suggesting a change of pharmacokinetic parameters of high-dose cyclo-phosphamide and cisplatin when given with an ondansetron-containing antiemetic regimen, see Gastrointestinal Drugs, p. 703.
Peak plasma concentrations of ondansetron occur about 1.5 hours after an oral dose of 8 mg, and about 6 hours after a rectal dose. The absolute bioavailability is about 60%, mainly because of hepatic first-pass metabolism. In elderly subjects, bioavailability may be somewhat higher (65%) and clearance lower, presumably due to reduced hepatic first-pass metabolism. Ondansetron is extensively distributed in the body about 70 to 75% of the drug in plasma is protein bound. It is metabolised in the liver through multiple enzymatic pathways ondansetron is a substrate for cytochrome P450 isoenzymes, primarily CYP3A4, but also CYP1A2 and CYP2D6. Less than 5% of a dose is excreted unchanged in the urine. The terminal elimination half-life is about 3 hours after oral or parenteral doses, and about 6 hours after rectal use. The terminal elimination half-life is prolonged to about 5 hours in the elderly and in those with renal impairment. These differences are not considered sufficient to warrant dosage adjustment. However, in patients with severe hepatic impairment, bioavailability may approach 100% and clearance is markedly reduced, with elimination half-lives of 15 to 32 hours dosage restriction is advisable (see Administration in Hepatic Impairment, below). In general, children have a higher clearance than adults, although age-related reductions in clearance have also been reported, with younger children having lower clearances. Use of weight-based doses compensates for these changes and normalises exposure in paediatric patients.
Uses and Administration
Ondansetron is a 5-HT3 antagonist (5-HT3-receptor antagonist) with antiemetic activity. It is used in the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. It is also used for the prevention and treatment of postoperative nausea and vomiting. For the management of nausea and vomiting, and the important role of 5-HT3 antagonists.
Ondansetron is given by intramuscular or slow intravenous injection or infusion as the hydrochloride, by mouth as the hydrochloride or base, or rectally as the base. Doses are expressed in terms of the base. Ondansetron hydrochloride 4.99 mg is equivalent to about 4 mg of ondansetron base. Numerous dosing schedules of ondansetron have been used some typical examples are cited below. For highly emetogenic chemotherapy the following dose schedules appear to be equally effective in preventing acute emesis:
• a single dose of 8 mg by slow intravenous or intramuscular injection immediately before treatment
• 8 mg by slow intravenous or intramuscular injection immediately before treatment, either followed by a continuous intravenous infusion of 1 mg/hour for up to 24 hours, or by a further two doses of 8 mg two to four hours apart
• a single dose of 32 mg given by intravenous infusion over at least 15 minutes immediately before treatment
• 150 micrograms/kg by intravenous infusion over 15 minutes, beginning 30 minutes before chemotherapy, and repeated 4 and 8 hours after the first dose
• a 16-mg suppository rectally, given 1 to 2 hours before treatment
• a single oral dose of 24 mg taken 30 minutes before the start of single-day chemotherapy
The efficacy of ondansetron in highly emetogenic chemotherapy may be enhanced by giving intravenous dexamethasone sodium phosphate 20 mg before chemotherapy.
Similar regimens to those given above are used for preventing acute emesis with less emetogenic chemotherapy and/or radiotherapy and also include:
• 8 mg can be given orally up to 2 hours before treatment followed by 8 mg 8 to 12 hours later
To protect against delayed emesis these regimens are followed by oral ondansetron 8 mg twice daily, or 16 mg rectally once daily, for up to 5 days after the end of a course of chemotherapy.
For children the licensed dose in the UK is 5 mg/m intravenously immediately before chemotherapy, followed by 4 mg orally 12 hours later. A dose of 4 mg orally twice daily may be continued for up to 5 days after the end of chemotherapy. The BNFC allows (in children aged 1 to 12 years) for 5 mg/m intravenously before chemotherapy (up to a maximum single dose of 8 mg), which can be repeated every 8 to 12 hours during chemotherapy and for at least 24 hours afterwards alternatively oral doses of 4 mg can be given every 8 to 12 hours for up to 5 days after intravenous use. In the USA a licensed regimen in children over 6 months of age is 150 micrograms/kg by intravenous infusion 30 minutes before chemotherapy, repeated 4 and 8 hours after the first dose. Alternatively, for children aged 4 to 11 years, an oral dose of 4 mg may be given 30 minutes before the start of chemotherapy, with subsequent 4-mg doses given 4 and 8 hours thereafter. An oral dose of 4 mg three times daily may be given for 1 to 2 days after the end of chemotherapy. To prevent postoperative nausea and vomiting adults may be given:
• 16 mg orally an hour before anaesthesia
• 8 mg orally an hour before anaesthesia followed by 2 further doses of 8 mg at 8-hour intervals
• a single dose of 4 mg by intramuscular or slow intravenous injection at induction of anaesthesia
For the treatment of postoperative nausea and vomiting a single 4-mg dose by intramuscular or slow intravenous injection is recommended.
In the UK, children aged 2 years and over may be given 100 micrograms/kg by slow intravenous injection, up to a maximum dose of 4 mg, both for the prevention and treatment of postoperative nausea and vomiting in the USA this dose is licensed from 1 month of age. In patients with moderate or severe hepatic impairment it is recommended that the total daily dose of ondansetron should not exceed 8 mg (see below).
Administration. Ondansetron has been successfully used by continuous subcutaneous infusion to control intractable nausea and vomiting. Despite concern about the low pH of ondansetron injection there was no problem with the skin at the infusion site. An oral protocol for chemotherapy-induced emesis in children has been described efficacy was similar to intravenous use.
Administration in hepatic impairment. Licensed drug information recommends that the dose of ondansetron should not exceed 8 mg daily in patients with moderate or severe hepatic impairment. When this dose was given intravenously to patients with hepatic impairment, those with severe impairment showed an increase in the area under the plasma concentration/time curve and in the terminal plasma half-life, and a decrease in plasma clearance. The authors of this study, some of whom worked for the manufacturers (Glaxo) considered that ondansetron should be restricted to once daily dosage in severe hepatic impairment.
Bulimia nervosa. A combination of counselling, support, psychotherapy, and antidepressants is the usual treatment of bulimia nervosa. Preliminary reports have indicated that ondansetron may be of benefit in the treatment of this disorder.’
Fatigue. Preliminary results indicated that treatment with 5-HT3 antagonists such as ondansetron and tropisetron may be of benefit in patients with chronic fatigue. Ondansetron 4 mg twice daily by mouth was reported to resolve fatigue in a woman with chronic hepatitis C. In a randomised study in 36 patients with chronic hepatitis C, this dose of ondansetron given for 1 month significantly improved fatigue scores at day 15 and day 60 (beyond the treatment period) when compared with placebo. The authors noted that patient awareness that constipation was a possible effect of active treatment may have potentially unblinded the study. Further confirmation by larger studies is needed.
Pain. Preliminary results from a small crossover study indicated that oral ondansetron was more effective than paracetamol in relieving the pain of fibromyalgia, a chronic disorder that responds poorly to conventional analgesics. A single bolus of ondansetron given to patients with chronic neuropathic pain significantly reduced pain scores 2 hours after injection in a placebo-controlled study this effect may be due to an action on 5-HT3 receptors in the spinal cord.
Other 5-HT3 antagonists such as granisetron and tropisetron have also been investigated in various painful syndromes.
Pruritus. There are several case reports’ of cholestatic pruritus responding to intravenous or oral ondansetron, including one in pregnancy. However, results from controlled studies have been mixed. It is similarly unclear if ondansetron is of benefit in pruritus due to renal failure, and results have been conflicting from controlled studies evaluating its use in opioid-induced pruritus. There are reports of ondansetron ameliorating the pruritus associated with some skin disorders. Other 5-HT3 antagonists such as tropisetron and dolasetron have also been investigated.
Psychiatric disorders. Ondansetron has been tried experimentally in a number of psychiatric disorders including schizophrenia, and psychosis in patients with parkinsonism, and may be of value in moderating tardive dyskinesia. A reduction in tic severity in Tourette’s syndrome has been reported, and preliminary results have suggested benefit in obsessive-compulsive disorder, and bulimia nervosa (see above). It is also reported to be under investigation in the management of panic attacks. For the more conventional management of schizophrenia, parkinsonism, and obsessive-compulsive disorder.
Substance dependence. Ondansetron is being studied in the management of alcohol dependence. However, in one study a significant reduction in alcohol consumption was found only in lighter drinkers after subgroup analysis. Another study found a reduction in alcohol consumption by patients with early-onset alcoholism (onset before age 25) who took ondansetron compared with placebo. No such effect was seen, however, in patients with late-onset alcoholism. Further study found that ondansetron also effectively ameliorated mood disturbances including symptoms of depression, anxiety, and hostility, in earlyonset alcoholics. Self-reported alcohol consumption also reduced in adolescents (between ages 14 and 20) with alcohol dependence who were given ondansetron in an open study.
The United States Pharmacopeia 31, 2008: Ondansetron Hydrochloride Oral Suspension; Ondansetron Injection; Ondansetron Oral Solution; Ondansetron Orally Disintegrating Tablet.
Argentina: Cetron Dantenk Dismolan Emivox Espasevit Finaber Finoxi Tiosalis Zofran
Australia: Ondaz Onsetron Zofran
Austria: Glaxosetron Ondanoglax Ondensan Zofran
Brazil: Ansentron Injectrax Modifical Nausedron Ontrax Vonau Zofran
Chile: Amilene Gardoton Izofran Odanex Oncoemet Trorix
Czech Republic: Danemet Emeset Emetron Novetron Ondemet Setron Setronon Zofran
Denmark: Hexatron Zofran
Greece: Biosetron Cruzafen Dentron Fedral Odnatron Onda Ondameton Ondaren Ondaseprol Setrodan Vefron Zetron Zodatron Zofron Zophralen
Hong Kong: Zofran
Hungary: Antivom Emetron Ondagen Zofran
India: Emeset Periset Vomiof
Indonesia: Cedantron Dantroxal Entron Frazon Invomit Narfoz Ondavell Onetic 4 Vomceran Zantron Zofran
Ireland: Emital Zofran
Malaysia: Osetron Zofran
Mexico: Danac Modifical Precirux Zofran
The Netherlands: Zofran
New Zealand: Onsetron Zofran
Philippines: Emodan Zofran
Poland: Atossa Emetron Setronon Zofran
Portugal: Nausiend Otobrol Zofran
Russia: Emetron Setronon Zofran
South Africa: Dantron Nausetron Zofran
Spain: Fixca Yatrox Zofran
Thailand: Dantron Emeset Onsia Vomitron Zetron Zofran
Turkey: Zofer Zofran Zoltem
UK: Ondemet Zofran
Venezuela: Dismolan Emeset Tructum Zofran